AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 14, 2022

The medical devices industry in the country has sought the Centre to define online and offline mode of sale, provide more clarity on the regulations that are binding the online sales and suggested inclusion of online medical devices players under the Uniform Code for Medical Devices Marketing Practices (UCMDMP).

Sales 182

Sales Regulation Marketing Drugs 182

Pharmaceutical Technology

FEBRUARY 8, 2023

The top 20 companies in the global biopharma industry saw 5.4%* aggregate market capitalization from $3.43 Pfizer maintained its third-place position in the market in 2022, reporting a market capitalization of $287.6 witnessed the biggest market capitalization growth of 45.3% trillion to $3.61 billion on Dec 31, 2022.

Marketing 195

Marketing Sales Vaccination Vaccine 195

XTalks

DECEMBER 19, 2024

Roches Alecensa is the current ALK inhibitor market leader. It entered the first-line ALK treatment landscape seven years ago following the Phase III ALEX trial. The trial demonstrated that Alecensa reduced the risk of disease progression or death by 47 percent compared to Xalkori. billion Swiss francs ($1.28

FDA Approval 98

FDA Approval Marketing Trials Drugs 98

Fierce Pharma

JUNE 17, 2024

Two back-to-back pivotal trial wins have rekindled hopes at GSK that once-failed multiple myeloma drug Blenrep could reach more than 3 billion pounds sterling in peak sales after all. |

Sales 108

Sales Marketing Trials Drugs 108

pharmaphorum

NOVEMBER 19, 2021

The race to find and bring vaccines to market to fight Covid was impressive. So too are the sales figures. Pfizer/BioNTech’s vaccine dominates the market. billion in vaccine sales this year. Together, these mRNA jabs have an iron grip on the covid vaccine market – in the US, they have consolidated a 90% market share.

Sales 137

Sales Vaccination Vaccine Marketing 137

pharmaphorum

DECEMBER 23, 2022

Rarely are organisations able to view HCP relationships holistically – across clinical, medical, and sales – or reap the benefits of creating a unified understanding of the customer. In 2023, omnichannel behaviours will directly influence incentive compensation models by correlating successful engagement data to successful sales outcomes.

Sales 105

Sales Marketing Life Science Compliance 105

Pharmaceutical Technology

APRIL 28, 2023

Novo Nordisk’s leading drug Ozempic (semaglutide) is forecast to demonstrate a sales growth of 23% in 2023. Ozempic’s forecast 2023 sales of $12.5bn consolidate its position as the dominant market leader, with projected sales in 2023 54% greater than closest competitor Trulicity (dulaglutide) by Eli Lilly, which anticipates sales of $8bn.

Sales 130

Sales Insulin Marketing FDA Approval 130

Pharmaceutical Technology

NOVEMBER 21, 2022

Japan is currently the fourth largest market in the world. Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 billion) in total sales in 2021 and is expected to grow 1.1% Other reasons include lower sales demand and high investment costs.

Marketing 173

Marketing Sales Manufacturing Drugs 173

Pharmaceutical Technology

MARCH 28, 2023

5 adapted bivalent Covid-19 vaccine, the company has forecasted a slump in sales for 2023 as Covid-19 vaccine demand falls. In response to the lower vaccine sales forecasts, BioNTech shares opened at 3.9% lower than the previous market day’s close. However, following its launch of the world’s first Omicron BA.4/BA.5

Vaccination 276

Vaccination Vaccine Development Clinical Trials 276

XTalks

NOVEMBER 21, 2024

Additionally, over a 176-week period, weekly injections of tirzepatide (marketed as Zepbound and Mounjaro) using pooled doses of 5 mg, 10 mg and 15 mg, significantly reduced the risk of disease progression to type 2 diabetes by 94 percent compared with placebo in adult prediabetes patients who were obese or overweight.

Sales 105

Sales Insulin Drugs Trials 105

Pharmaceutical Technology

JUNE 7, 2023

Eli Lilly has achieved significant gains in the past quarter, leading to it becoming the most valuable pharmaceutical company in the world, with a market cap of $420bn, surpassing Johnson & Johnson. There have been several Phase III trials for Mounjaro, with SURMOUNT-1 demonstrating a weight loss of up to 22.5%

Marketing 246

Marketing Sales Trials Drugs 246

Fierce Pharma

MAY 6, 2024

As BioNTech continues to endure a sharp decline in COVID-19 vaccine sales, the German mRNA specialist is looking ahead to the next leg of its commercial journey. With plans to have at least 10 potentially registrational trials underway by the end of 2024, BioNTech is plotting the first wave of its market debut in oncology from 2026 onward.

Sales 118

Sales Vaccination Vaccine Trials 118

Pharmaceutical Technology

AUGUST 30, 2022

International companies investing in the emerging market of Brazilian pharmaceutical manufacturing will see a higher return on investment than from developed market equivalents, if they choose to compete with local manufacturers to supply Brazil’s growing market and the greater South American region.

Manufacturing 195

Manufacturing Marketing Pharma Companies Vaccination 195

Pharmaceutical Technology

DECEMBER 15, 2022

In an expanded version of the sales forecast from GlobalData’s June 2022 publication, Cardiomyopathies: Global Drug Forecast and Market Analysis , the global cardiomyopathies market is expected to grow from $3.07bn last year to $9.63bn in 2031. of sales in 2021 and 2031 respectively.

Marketing 130

Marketing Sales Clinical Trials Clinical Trials 130

AuroBlog - Aurous Healthcare Clinical Trials blog

JULY 10, 2022

A new anti-hangover supplement has just gone on sale in the UK. It is marketed by Swedish firm Myrkl as “the pre-drinking pill that works” The pill is said to break down up to 70 percent of alcohol after 60 minutes. This means that if someone drinks 50 ml of 40 percent spirits, which contains […].

Containment 246

Containment Sales Marketing Clinical Trials 246

pharmaphorum

NOVEMBER 22, 2022

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market. The post GSK will pull Blenrep from US market after failed trial appeared first on.

Marketing 105

Marketing Trials Antibody Clinical Trials 105

World of DTC Marketing

FEBRUARY 7, 2022

According to Endpoint News” We’ve seen Biogen’s CSO exit under pressure in recent weeks, and senior marketing execs leave in an exodus as the company recoiled from a fierce backlash against the FDA’s ultra controversial approval of Aduhelm for Alzheimer’s. Finally, they need to withdraw Aduhelm from the market.

Pharma Companies 253

Pharma Companies Marketing Sales Clinical Trials 253

Pharmaceutical Technology

OCTOBER 31, 2022

The osteoarthritis (OA) market was valued at $2.5 billion in the 7MM (seven major markets) in 2021, and is expected to increase to $3.8 These are forecast to contribute significantly towards sales in the OA market in 2031, accounting for 10% and 14.2% of the 7MM sales, respectively. in the US).

Marketing 147

Marketing Sales Clinical Trials Clinical Trials 147

Pharmaceutical Technology

NOVEMBER 8, 2022

Additionally, Neurophth will oversee the clinical trials and marketing of gene therapy products developed leveraging the new AAV capsids of Cyagen. Under the collaboration, Cyagen is entitled to get research phase and clinical phase milestone payments and sales-based royalty payments totalling over $140m.

Gene Therapy 305

Gene Therapy Gene Development Genetics 305

Pharmaceutical Technology

OCTOBER 21, 2022

On concluding this trial, Roche will gain the right to develop and market the licenced products across various indications, contingent on approval. Following the marketing of both programmes, Hookipa will also receive tiered royalty payments on the global net product sales.

Development 278

Development Production Licensing Licensing 278

Pharmaceutical Technology

MAY 16, 2023

More than half of the top 20 global biopharmaceutical companies saw a fall in market capitalisation over Q1 2023. decline in total aggregate market capitalisation from $3.61 Bayer reported the highest market capitalisation growth of 23.1% Sanofi and Regeneron’s market capitalisation grew by 12.4% This resulted in a 3.4%

Marketing 130

Marketing Sales Generic Drugs Vaccination 130

Pharmaceutical Technology

NOVEMBER 25, 2022

Novo Nordisk further exemplified this in its announcement on November 4, 2022, where they revealed that there had been a growth in sales for Ozempic. However, Wegovy is a current favorite within the obesity market due to its superior efficacy benefits in comparison to the other GLP-1 receptor agonist, Saxenda.

Marketing 279

Marketing Production Sales Trials 279

World of DTC Marketing

AUGUST 9, 2021

86% of diagnostic device companies, 65% of pharma marketers, and over half of biotechs use social as a critical part of their marketing mix to reach HCPs. The best approach is to use social media to connect HCPs to clincial information and drug trials. Doximity was flagged for having anti-vaccine information.

Nurses 294

Nurses Marketing Pharma Companies Production 294

Velocity Clinical Research

MARCH 23, 2025

Clinical trials have been steadily leaving the UK for years. of patients recruited to global trials were from the UK. Thats not to say we dont still have some clout (the UK ranks fourth globally for Phase II trials ), but the trending outflow needs to be addressed. In 2021, just 2.2% So, delays cost money, and the NHS is slow.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Life Science 52

Pharmaceutical Technology

MAY 19, 2023

Rinvoq is a major pillar in AbbVie’s plan to stem revenue drops once biosimilars to its behemoth Humira (adalimumab) enter the market on a sustained basis this year. AbbVie anticipates Rinvoq sales to exceed $7.5bn in 2025 and for the peak revenues from both drugs to exceed Humira’s peak sales by 2027.

FDA Approval 264

FDA Approval Dermatology Sales Clinical Trials 264

Pharmaceutical Technology

DECEMBER 19, 2022

Innate is also eligible to receive a total of up to $1.43bn (€1.35bn) in preclinical, clinical, regulatory and commercial milestone payments and royalty payments on net sales in the future. On choosing the candidate, the company will oversee the complete development, production and marketing.

Development 264

Development Engineer Clinical Trials Clinical Trials 264

Pharmaceutical Technology

JANUARY 19, 2023

Acute myeloid leukemia (AML) is part of a market of blood malignancies that commercial cell therapies have not managed to penetrate yet. None of these products are in a registrational trial, and as such, GlobalData does not anticipate their entry into the AML market earlier than 2028.

Marketing 130

Marketing Gene Editing Production Sales 130

Pharmaceutical Technology

OCTOBER 28, 2022

On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. VAX-24 has forecasted sales of $21 million in the same year. Competition in an increasingly heated market.

Vaccination 162

Vaccination Vaccine Marketing Bacteria 162

pharmaphorum

AUGUST 8, 2022

As we reported this morning, the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon could see a dramatic uptick in sales with Pfizer’s marketing muscle – plus a phase 3 antibody candidate, a phase 1 follow-up to Oxbryta that could offer improved dosing.

Marketing 111

Marketing Sales Gene Editing Antibody 111

Pharmaceutical Technology

NOVEMBER 21, 2022

Japan is currently the fourth largest market in the world. Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 billion) in total sales in 2021 and is expected to grow 1.1% Other reasons include lower sales demand and high investment costs.

Marketing 130

Marketing Sales Manufacturing Drugs 130

World of DTC Marketing

JUNE 2, 2021

SUMMARY: Doctors said they were dissatisfied were marketing emails (46%), telephone sales calls with sales reps (42%), and both webinars and websites (each at 39%) from pharma companies, according to Indegene. It can’t be promotional or sales information and should not be a long document. 100 percent of U.S.

Doctors 180

Doctors Doctor Sales Marketing 180

World of DTC Marketing

JANUARY 11, 2022

As HCPs get more digitally savvy, pharma marketers should understand that engaging physicians through channels and time of their preference with content relevant to the individual customer. is no more an option but a critical factor to ensure success for any multichannel marketing initiatives.

Pharma Companies 235

Pharma Companies Sales Marketing Clinical Trials 235

Pharmaceutical Technology

JULY 13, 2022

Merck (MSD outside North America) and Orion have entered an international agreement to develop and market the latter’s investigational candidate ODM-208 to treat metastatic castration-resistant prostate cancer (mCRPC). As per the agreement, the companies will jointly develop and market ODM-208.

Development 264

Development Hormones Production Marketing 264

XTalks

FEBRUARY 24, 2025

Carlsbad, California-based Ionis Pharmaceuticals announced it will be sharing promising new trial data for its RNA-targeted prophylactic treatment donidalorsen for hereditary angioedema (HAE) at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress in San Diego, California.

Trials 59

Trials RNA Allergies Drugs 59

pharmaphorum

MAY 24, 2022

It powers drug discovery, clinical trials, and operational performance. Organisations are missing out on the ability to harness their data to energise precision marketing and transform commercial performance. Securing advantages and market share is growing tougher. Deeper Insights. Single View of HCPs.

Marketing 111

Marketing Sales Life Science Pharma Companies 111

Pharmaceutical Technology

MAY 15, 2023

Sanofi announced data from a real-world clinical trial that demonstrated its RSV antibody nirsevimab delivered an 83% reduction in hospitalisations in infants with respiratory syncytial virus (RSV)-related lower respiratory tract disease (LRTD). Nirsevimab is being jointly developed between Sanofi and AstraZeneca.

Antibody 245

Antibody Vaccination Vaccine Trials 245

Pharmaceutical Technology

JUNE 12, 2023

In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. Six cannabinoids have recently completed or are undergoing Phase II trials. A promising example includes Vertex Pharmaceuticals’s VX-548, a sodium channel subunit blocker.

Drugs 358

Drugs Development Clinical Development Sales 358